Previous research has indicated that both the inhibition of GSK-3β and the increase of glycogen synthase activity in the liver are beneficial for type 2 diabetic patients, which suggests that the inhibition of GSK-3β in the liver could be a third MT function beneficial for patients suffering from type 2 diabetes53, 54. Here, GSK3B is linked to type 2 diabetes mellitus.